Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be \>=18 years and \<=75 years of age, male or female.~* Primary hypercholesterolemic subject with a plasma LDL cholesterol concentration \>3.64 mmol/L (140 mg/dL) to \<=6.3 mmol/L (250 mg/dL) using the Friedewald calculation; total cholesterol (TC) \>5.2 mmol/L (200 mg/dL) to \<12.7 mmol/L (500 mg/dL) and triglyceride concentrations of \<=3.99 mmol/L (350 mg/dL) should be met at the same time. At the time of recruitment (Visit 1), these values may be lower if the subject is on lipid-lowering therapy. (ie, prior to the start of lipid lowering drug washout) or may be higher at the start of dietary therapy.~* Liver transaminases (ALT, AST) \<=50% above the upper limit of normal, with no active liver disease and CK \<=50% above the upper limit of normal.~* Clinical laboratory tests (complete blood count \[CBC\], blood chemistries, urinalysis) must be within normal limits, or clinically acceptable to the investigator/sponsor.~* Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control.~* Subjects must be free of any clinically significant diseases other than hyperlipidemia that would interfere with study evaluations.~* Subjects must understand and be able to adhere to the dosing and visit schedules.~* Subject must agree to remain on a cholesterol-lowering diet for the duration of the study (according to China Adult Treatment Panel of High Blood Cholesterol).~Exclusion Criteria:~* Subjects whose body mass index (BMI=weight \[kg\]/height2 \[m\]) is \>=30 kg/m2 at Visit 3 (Baseline Visit).~* Subjects who have known hypersensitivity to HMG CoA reductase inhibitors.~* Subjects who consume \>14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).~* Any condition or situation, which in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.~* Women who are pregnant or nursing.~* Subjects who have not observed the designated washout periods for any of the prohibited medications.~* Congestive heart failure defined by NYHA as Class III or IV.~* Uncontrolled cardiac arrhythmia.~* Myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of study entry.~* Unstable or severe peripheral artery disease within 3 months of study entry.~* Unstable angina pectoris within 6 months of study entry.~* Uncontrolled hypertension (treated or untreated) with systolic blood pressure \>160 mm Hg or diastolic \>100 mm Hg at study entry.~* Uncontrolled (as determined by fasting glucose \>180 mg/mL or HbA1c \>9%) or newly diagnosed (within 1 month of study entry) diabetes mellitus.~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, ie, secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone \[TSH\] above upper limit of normal). Subjects with a history of hypothyroidism who are on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible for enrollment if TSH levels are within normal limits before enrollment.~* Known impaired renal function (plasma creatinine \>2.0 mg/dL), or nephrotic syndrome at study entry.~* Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.~* Known HIV positive.~* Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).~* History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.~* Female subject receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vytorin 10/10 (Type: EXPERIMENTAL): Ezetimibe 10 mg with Simvastatin 10 mg
- Vytorin 10/20 (Type: EXPERIMENTAL): Ezetimibe 10 mg with Simvastatin 20 mg
- Vytorin 10/40 (Type: EXPERIMENTAL): Ezetimibe 10 mg with Simvastatin 40 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).